Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants ≥ 2 and < 43 months of Age: A phase III, multicenter, active controlled, assessor-blinded, randomized, parallel-group study

Vaccine. 2024 Apr 30;42(12):3134-3143. doi: 10.1016/j.vaccine.2023.03.077. Epub 2024 Apr 6.

Abstract

Objective: This study investigated the immunogenicity and safety of a pentavalent vaccine Gobik (DPT-IPV-Haemophilus influenzae type b [Hib]) in healthy Japanese infants aged ≥ 2 and < 43 months using a concomitant vaccination with ActHIB® (Hib) and Tetrabik (DPT-IPV) as a comparator.

Methods: This study was conducted as a phase 3, multicenter, active controlled, assessor-blinded, randomized, parallel-group study. Participants received a total of 4 subcutaneous doses (3 primary immunization doses and a booster dose) of either the experimental drug (DPT-IPV-Hib) or the active comparator (Hib + DPT-IPV). The primary endpoints were the anti-PRP antibody prevalence rate with ≥ 1 μg/mL, and the antibody prevalence rates against pertussis, diphtheria toxin, tetanus toxin, and attenuated poliovirus after the primary immunization.

Results: In 267 randomized participants (133 in the DPT-IPV-Hib group and 134 in the Hib + DPT-IPV group), the antibody prevalence rates after the primary immunization in both groups were 100.0 % and 88.7 % for anti-PRP antibody with ≥ 1 μg/mL, 99.2 % and 98.5 % against diphtheria toxin, and 100.0 % and 99.2 % against tetanus toxin, respectively. The antibody prevalence rates against pertussis and attenuated poliovirus were 100.0 % in both groups. The non-inferiority of the DPT-IPV-Hib group to the Hib + DPT-IPV group was verified for all measured antibodies. In both groups, all the GMTs of antibodies after the primary immunization were higher than those before the first dose, and those after the booster dose were higher than those after the primary immunization. No safety issues were identified.

Conclusion: A single-agent Gobik, the first DPT-IPV-Hib pentavalent vaccine approved in Japan, was confirmed to simultaneously provide primary and booster immunizations against Hib infection, pertussis, diphtheria, tetanus, and poliomyelitis and to have a preventive effect and safety comparable to concomitant vaccination with Hib (ActHIB®) and DPT-IPV quadrivalent vaccine (Tetrabik).

Keywords: Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio Combined Vaccine; DPT-IPV; DPT-IPV-Hib; Haemophilus influenzae type b; Hib; Infants.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study
  • Clinical Trial, Phase III

MeSH terms

  • Antibodies, Bacterial
  • Diphtheria Toxin
  • Diphtheria* / prevention & control
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines*
  • Haemophilus influenzae type b*
  • Humans
  • Immunization Schedule
  • Infant
  • Japan
  • Poliomyelitis* / prevention & control
  • Poliovirus Vaccine, Inactivated
  • Tetanus Toxin
  • Tetanus* / prevention & control
  • Vaccines, Combined
  • Vaccines, Conjugate
  • Whooping Cough* / prevention & control

Substances

  • Tetanus Toxin
  • Diphtheria Toxin
  • Poliovirus Vaccine, Inactivated
  • Antibodies, Bacterial
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Vaccines, Combined
  • Vaccines, Conjugate
  • Haemophilus Vaccines